In this article, Ahmed A. Hussein, MD, and James F. Smith, MD, MS, examine the effect of malignancy and anti-cancer treatment on fertility, review current fertility preservation methods, and offer a preview of fertility preservation techniques that hold future promise.
The FDA’s approval of enzalutamide (XTANDI) to treat metastatic castration-resistant prostate cancer (CRPC) in the pre-chemotherapy setting is a potential game changer for both patients and treating physicians, especially urologists, according to leaders in the prostate cancer field.
Physical activity lowers men’s risk of developing nocturia and should be recommended to patients with the condition, a leading men’s health expert and Urology Times Editorial Council member says.
Metastatic castration-resistant prostate cancer patients whose tumors contain the androgen receptor (AR)-V7 splice variant are less likely to respond to enzalutamide (XTANDI) and abiraterone acetate (ZYTIGA), recent study results indicate.
Low testosterone is often blamed for a lower sex drive and potentially dangerous fat accumulation in men, however researchers from Massachusetts General Hospital report that a lack of estrogen is also to blame. Video provided by Renal & Urology News.
University of Utah Health Care - William O. Brant, M.D., discusses the causes and diagnosis of erectile dysfunction (ED).
This video presents a thorough description of all the treatment options available for erectile dysfunction, including their administration, benefits, and limitations.
In this first installment of UrologyTimes.com's new video section, called ‘Y’tube, we present videos from high-volume prosthetic surgeons performing inflatable penile prosthesis (IPP) placement and discussing diagnosis and management of ED. William O. Brant, MD, offers the following general commentary about these procedures, as well as specific comments in the text accompanying each individual video.
In these videos, H. Ballentine Carter, MD, discusses the evidence supporting active surveillance, and Leonard S. Marks, MD, and colleagues outline which men are good candidates for surveillance.
Men who eat over 10 portions a week of tomatoes have an 18% lower risk of developing prostate cancer, according to a newly published study from the United Kingdom.
As it becomes apparent that more prostate cancers are clinically insignificant than previously believed, the role of active surveillance in the management of men with low-risk prostate cancer merits expansion.
Steven A. Kaplan, MD, introduces #LetsTalkMensHealth, a novel new section in Urology Times focused on men’s health.
Other products featured include a testosterone gel, exercise program to strengthen male pelvic muscles, and a book about prostate cancer diagnosis and management.
Transrectal ultrasound-guided prostate biopsy is associated with a rising rate of hospitalization for urinary tract infection, new study results indicate.
Presentations of phase III data at the American Society of Clinical Oncology annual meeting in Chicago further support the conclusion that the oral androgen receptor inhibitor enzalutamide (XTANDI) addresses an unmet therapeutic need for metastatic castration-resistant prostate cancer in the pre-chemotherapy setting.
A recent study confirms that treatment choices for localized prostate cancer are not stagnant but continue to evolve, writes Leonard G. Gomella, MD.
A retrospective evaluation to determine adherence to the AUA clinical practice guideline for the management of lower urinary tract symptoms/BPH among urologists practicing in an academic setting found generally positive results, but with room for improvement, researchers reported at the AUA annual meeting in Orlando, FL.
The question of what role urologists should play in managing hormone-resistant prostate cancer is "controversial," says Kenneth Jacobsohn, MD.
Sexual function in men with lower urinary tract symptoms/BPH generally declines over time whether or not they are treated with medication. However, the magnitude of worsening differs depending on the treatment received, according to findings from the Medical Therapy of Prostatic Symptoms study.
Photoselective vaporization of the prostate is non-inferior to transurethral resection of the prostate in men with benign prostatic obstruction, researchers reported at the European Association of Urology annual congress in Stockholm, Sweden.
Use of surgery has increased steadily among all men with clinically localized prostate cancer, and in those with low-risk disease, brachytherapy utilization has declined.
A significant number of older men with limited life expectancy continue to undergo routine prostate cancer screening, researchers say.
The Androgen Study Group has called upon the Journal Oversight Committee to investigate what it deemed violations of “accepted standards of medical journal ethics and editorial integrity” by JAMA.
Data from 2 years of prospective follow-up in a multinational study show that the prostatic urethral lift (PUL [UroLift System, Neotract, Inc., Pleasanton, CA]) is a safe procedure that provides durable, clinically meaningful improvement of lower urinary tract symptoms due to BPH, reported Claus G. Roehrborn, MD, at the AUA annual meeting in Orlando, FL.
Drugs and devices in the pipeline form Clarus Therapeutics, Nymox Pharmaceutical, Bioniche Life Sciences, Repros Therapeutics, BioLight Life Sciences Investments/Micromedic Technologies, Cubist Pharmaceuticals, Takeda Pharmaceutical, H. Lundbeck A/S, Transplant Genomics, Orion, Bayer, and Roche.
